Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc.AUPH · Entity 4463 | Director | June 04, 2026 | June 08, 2026 |
| LANDAUER INCLDR · Entity 172389 | Director | October 19, 2017 | October 19, 2017 |
| Rein Therapeutics, Inc.ALRN · Entity 7071 | Director | June 15, 2020 | June 17, 2022 |
| abrdn Healthcare InvestorsHQH · Entity 8816 | Director | September 23, 2020 | September 23, 2020 |
| abrdn Healthcare Opportunities FundTHQ · Entity 5102 | Director | September 23, 2020 | September 23, 2020 |
| abrdn Life Sciences InvestorsHQL · Entity 8835 | Director | September 22, 2020 | September 23, 2020 |
| abrdn World Healthcare FundTHW · Entity 5390 | Director | April 06, 2021 | April 08, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aurinia Pharmaceuticals Inc.
Report date June 04, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.67 · Expires 2036-06-04 | Direct | 23,931 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 23,931 · Balance 23,931 F1: The options shall vest one year from date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The options shall vest one year from date of grant.
LANDAUER INC
Report date October 19, 2017 · Filed October 19, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-10-19 transaction · row 1
1 source rowRow 1 · 2017-10-19 · Disposition to issuer · Disposed 8,943 · Balance 0 F1: Pursuant to an Agreement and Plan of Merger, dated September 6, 2017 (the ?Merger Agreement?), by and among Fern Merger Sub Inc., a Delaware corporation (?Purchaser?) and an indirect wholly owned subsidiary of Fortive Corporation, a Delaware corporation, and Landauer, Inc., a Delaware corporation (the ?Issuer?), each outstanding share of the Issuer?s common stock was disposed of pursuant to the closing on October 19, 2017 of a cash tender offer by Purchaser to acquire common stock of Issuer in exchange for $67.25 per share in cash, subject to any required withholding of taxes, without interest. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to an Agreement and Plan of Merger, dated September 6, 2017 (the ?Merger Agreement?), by and among Fern Merger Sub Inc., a Delaware corporation (?Purchaser?) and an indirect wholly owned subsidiary of Fortive Corporation, a Delaware corporation, and Landauer, Inc., a Delaware corporation (the ?Issuer?), each outstanding share of the Issuer?s common stock was disposed of pursuant to the closing on October 19, 2017 of a cash tender offer by Purchaser to acquire common stock of Issuer in exchange for $67.25 per share in cash, subject to any required withholding of taxes, without interest.
Rein Therapeutics, Inc.
Report date June 15, 2020 · Filed June 17, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.40 · Expires 2032-06-14 | Direct | 54,500 |
Reported balance
After 2022-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-15 · Grant · Acquired 54,500 · Balance 54,500 F1: This option was granted on June 15, 2022. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 15, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 15, 2022. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 15, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders.
abrdn Healthcare Investors
Report date September 23, 2020 · Filed September 23, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Shares of Beneficial InterestSEC Table I · non-derivative | Direct | 490 |
Reported balance
After 2020-09-23 transaction · row 1
1 source rowRow 1 · 2020-09-23 · Purchase · Acquired 490 · Balance 490 |
abrdn Healthcare Opportunities Fund
Report date September 23, 2020 · Filed September 23, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Shares of Beneficial InterestSEC Table I · non-derivative | Direct | 570 |
Reported balance
After 2020-09-23 transaction · row 1
1 source rowRow 1 · 2020-09-23 · Purchase · Acquired 570 · Balance 570 |
abrdn Life Sciences Investors
Report date September 22, 2020 · Filed September 23, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Shares of Beneficial InterestSEC Table I · non-derivative | Direct | 580 |
Reported balance
After 2020-09-22 transaction · row 1
1 source rowRow 1 · 2020-09-22 · Purchase · Acquired 580 · Balance 580 |
abrdn World Healthcare Fund
Report date April 06, 2021 · Filed April 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Shares of Beneficial InterestSEC Table I · non-derivative | Direct | 980 |
Reported balance
After 2021-04-06 transaction · row 1
1 source rowRow 1 · 2021-04-06 · Other · Acquired 245 · Balance 980 |
| Subscription RightsSEC Table II · derivative / convertible security · Conversion / exercise price $14.26 · Expires 2021-04-06 | Direct | 0 |
Reported balance
After 2021-04-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-04-06 · Other · Disposed 735 · Balance 0 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIODELIVERY SCIENCES INTERNATIONAL INC
Report date March 22, 2022 · Filed March 22, 2022
Section 16 reporting ended · disclosed 2022-03-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-03-22 transaction · row 1
1 source rowRow 1 · 2022-03-22 · Other · Disposed 105,133 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 14, 2022, by and among the Issuer, Collegium Pharmaceutical, Inc., ("Parent"), and Bristol Acquisition Company Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of Issuer, $0.001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of March 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $5.60 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2022-03-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-03-22 · Disposition to issuer · Disposed 316,919 · Balance 0 F2: Each restricted stock unit ("RSU") represents the contingent right to receive one Share. F3: Each Issuer RSUs that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the Merger Consideration. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.18 | Direct | 0 |
Reported balance
After 2022-03-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-03-22 · Disposition to issuer · Disposed 96,000 · Balance 0 F4: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.23 | Direct | 0 |
Reported balance
After 2022-03-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-03-22 · Disposition to issuer · Disposed 160,000 · Balance 0 F4: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.36 | Direct | 0 |
Reported balance
After 2022-03-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-03-22 · Disposition to issuer · Disposed 66,805 · Balance 0 F4: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.60 | Direct | 0 |
Reported balance
After 2022-03-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-03-22 · Disposition to issuer · Disposed 840,000 · Balance 0 F4: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.66 | Direct | 0 |
Reported balance
After 2022-03-22 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-03-22 · Disposition to issuer · Disposed 1,143,467 · Balance 0 F4: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 14, 2022, by and among the Issuer, Collegium Pharmaceutical, Inc., ("Parent"), and Bristol Acquisition Company Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of Issuer, $0.001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of March 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $5.60 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.
F2: Each restricted stock unit ("RSU") represents the contingent right to receive one Share.
F3: Each Issuer RSUs that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the Merger Consideration.
F4: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 8, 2026 20:08 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantDirector Stock Option (right to buy) · Derivative | 23,931 | $0.00 Strike: $15.67 | $0.00 |
DisclosureSEC source: 0001500210-26-000002 · wk-form4_1780949328.xml · derivative · entry 1 Bailey Jeffrey Allen · CIK 0001500210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,931 Underlying: Common Shares · 23,931 shares Expires 2036-06-04 F1 · derivative.exercise_date: The options shall vest one year from date of grant. Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 22:19 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Tax withholdingCommon Shares | 2,716 | $15.68 | $42,586.88 |
DisclosureSEC source: 0001600620-25-000110 · wk-form4_1764022752.xml · nonDerivative · entry 1 Bailey Jeffrey Allen · CIK 0001500210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,775 F1 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units. Read SEC document |
| May 16, 2025 Filed May 16, 2025 21:04 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantDirector Stock Option (right to buy) · Derivative | 37,485 | $0.00 Strike: $8.15 | $0.00 |
DisclosureSEC source: 0001600620-25-000075 · wk-form4_1747429452.xml · derivative · entry 1 Bailey Jeffrey Allen · CIK 0001500210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,485 Underlying: Common Shares · 37,485 shares Expires 2035-05-16 F1 · derivative.exercise_date: The options shall vest one year from date of grant. Read SEC document |
| November 21, 2024 Filed Nov 25, 2024 21:30 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantDirector Stock Option (right to buy) · Derivative | 18,641 | $0.00 Strike: $8.24 | $0.00 |
DisclosureSEC source: 0001600620-24-000120 · wk-form4_1732570246.xml · derivative · entry 2 Bailey Jeffrey Allen · CIK 0001500210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,641 Underlying: Common Shares · 18,641 shares Expires 2034-11-21 F2 · derivative.exercise_date: The options shall vest one year from date of grant. Read SEC document |
| November 21, 2024 Filed Nov 25, 2024 21:30 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantCommon Shares | 12,135 | $0.00 | $0.00 |
DisclosureSEC source: 0001600620-24-000120 · wk-form4_1732570246.xml · nonDerivative · entry 1 Bailey Jeffrey Allen · CIK 0001500210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,491 F1 · shares: Represents grant of Restricted Stock Units (RSUs) payable solely in common shares of the Issuer. The shares subject to the RSUs shall vest one year from date of grant. Read SEC document |
| November 11, 2024 Filed Nov 13, 2024 00:29 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 4,557 | $8.43 | $38,415.51 |
DisclosureSEC source: 0001600620-24-000116 · wk-form4_1731457775.xml · nonDerivative · entry 2 Bailey Jeffrey Allen · CIK 0001500210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,356 F2 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of RSUs. F3 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.37 to $8.47, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| November 08, 2024 Filed Nov 13, 2024 00:29 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionRestricted Stock Units · Derivative | 17,913 | $0.00 | $0.00 |
DisclosureSEC source: 0001600620-24-000116 · wk-form4_1731457775.xml · derivative · entry 3 Bailey Jeffrey Allen · CIK 0001500210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,913 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs vested one year from date of grant and have no expiration date. F4 · derivative.expiration_date: The RSUs vested one year from date of grant and have no expiration date. Read SEC document |
| November 08, 2024 Filed Nov 13, 2024 00:29 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionCommon Stock | 17,913 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001600620-24-000116 · wk-form4_1731457775.xml · nonDerivative · entry 1 Bailey Jeffrey Allen · CIK 0001500210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 18, 2023 Filed Aug 21, 2023 20:25 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantStock Option (right to buy) · Derivative | 28,959 | $0.00 Strike: $9.49 | $0.00 |
DisclosureSEC source: 0001600620-23-000038 · wk-form4_1692649498.xml · derivative · entry 2 Bailey Jeffrey Allen · CIK 0001500210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,959 Underlying: Common Stock · 28,959 shares Expires 2033-08-18 F2 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing on September 18, 2023. Read SEC document |
| August 18, 2023 Filed Aug 21, 2023 20:25 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantRestricted Stock Units · Derivative | 17,913 | $0.00 | $0.00 |
DisclosureSEC source: 0001600620-23-000038 · wk-form4_1692649498.xml · derivative · entry 1 Bailey Jeffrey Allen · CIK 0001500210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,913 Underlying: Common Stock · 17,913 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest one year from date of grant and have no expiration date. Vested shares will be delivered on August 18, 2024. F1 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest one year from date of grant and have no expiration date. Vested shares will be delivered on August 18, 2024. F1 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest one year from date of grant and have no expiration date. Vested shares will be delivered on August 18, 2024. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 21:10 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 54,500 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0000899243-22-023133 · doc4.xml · derivative · entry 1 Bailey Jeffrey Allen · CIK 0001500210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,500 Underlying: Common Stock · 54,500 shares Expires 2032-06-14 F1 · derivative.exercise_date: This option was granted on June 15, 2022. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 15, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders. Read SEC document |
| March 22, 2022 Filed Mar 22, 2022 17:11 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Disposition to issuerStock Options (right to buy) · Derivative | 1,143,467 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0001103021-22-000065 · wf-form4_164798344795443.xml · derivative · entry 7 Bailey Jeffrey Allen · CIK 0001500210 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,143,467 shares Expires not disclosed F4 · price: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F4 · derivative.exercise_date: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F4 · derivative.expiration_date: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. Read SEC document |
| March 22, 2022 Filed Mar 22, 2022 17:11 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Disposition to issuerStock Options (right to buy) · Derivative | 840,000 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001103021-22-000065 · wf-form4_164798344795443.xml · derivative · entry 6 Bailey Jeffrey Allen · CIK 0001500210 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 840,000 shares Expires not disclosed F4 · price: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F4 · derivative.exercise_date: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F4 · derivative.expiration_date: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. Read SEC document |
| March 22, 2022 Filed Mar 22, 2022 17:11 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Disposition to issuerStock Options (right to buy) · Derivative | 66,805 | $0.00 Strike: $4.36 | $0.00 |
DisclosureSEC source: 0001103021-22-000065 · wf-form4_164798344795443.xml · derivative · entry 5 Bailey Jeffrey Allen · CIK 0001500210 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 66,805 shares Expires not disclosed F4 · price: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F4 · derivative.exercise_date: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F4 · derivative.expiration_date: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. Read SEC document |
| March 22, 2022 Filed Mar 22, 2022 17:11 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Disposition to issuerStock Options (right to buy) · Derivative | 160,000 | $0.00 Strike: $4.23 | $0.00 |
DisclosureSEC source: 0001103021-22-000065 · wf-form4_164798344795443.xml · derivative · entry 4 Bailey Jeffrey Allen · CIK 0001500210 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 160,000 shares Expires not disclosed F4 · price: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F4 · derivative.exercise_date: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F4 · derivative.expiration_date: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. Read SEC document |
| March 22, 2022 Filed Mar 22, 2022 17:11 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Disposition to issuerStock Options (right to buy) · Derivative | 96,000 | $0.00 Strike: $5.18 | $0.00 |
DisclosureSEC source: 0001103021-22-000065 · wf-form4_164798344795443.xml · derivative · entry 3 Bailey Jeffrey Allen · CIK 0001500210 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 96,000 shares Expires not disclosed F4 · price: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F4 · derivative.exercise_date: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F4 · derivative.expiration_date: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. Read SEC document |
| March 22, 2022 Filed Mar 22, 2022 17:11 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Disposition to issuerRestricted Stock Units · Derivative | 316,919 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001103021-22-000065 · wf-form4_164798344795443.xml · derivative · entry 2 Bailey Jeffrey Allen · CIK 0001500210 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 316,919 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one Share. F3 · price: Each Issuer RSUs that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the Merger Consideration. F3 · derivative.exercise_date: Each Issuer RSUs that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the Merger Consideration. F3 · derivative.expiration_date: Each Issuer RSUs that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the Merger Consideration. Read SEC document |
| March 22, 2022 Filed Mar 22, 2022 17:11 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | OtherCommon Stock | 105,133 | $0.00 | $0.00 |
DisclosureSEC source: 0001103021-22-000065 · wf-form4_164798344795443.xml · nonDerivative · entry 1 Bailey Jeffrey Allen · CIK 0001500210 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 14, 2022, by and among the Issuer, Collegium Pharmaceutical, Inc., ("Parent"), and Bristol Acquisition Company Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of Issuer, $0.001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of March 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $5.60 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes. F1 · shares: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 14, 2022, by and among the Issuer, Collegium Pharmaceutical, Inc., ("Parent"), and Bristol Acquisition Company Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of Issuer, $0.001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of March 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $5.60 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 14, 2022, by and among the Issuer, Collegium Pharmaceutical, Inc., ("Parent"), and Bristol Acquisition Company Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of Issuer, $0.001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of March 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $5.60 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 08:08 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 5,333 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001103021-22-000053 · wf-form4_164700411850804.xml · derivative · entry 2 Bailey Jeffrey Allen · CIK 0001500210 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,334 Underlying: Common Stock · 5,333 shares Expires 2023-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 5,333 of RSUs granted to the Reporting Person on March 9, 2020 under the Issuer's 2019 Stock Option Incentive Plan. The remainder of the RSUs under this grant will vest on March 9, 2023. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 08:08 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 5,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001103021-22-000053 · wf-form4_164700411850804.xml · nonDerivative · entry 1 Bailey Jeffrey Allen · CIK 0001500210 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,133 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 5,333 of RSUs granted to the Reporting Person on March 9, 2020 under the Issuer's 2019 Stock Option Incentive Plan. The remainder of the RSUs under this grant will vest on March 9, 2023. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 18:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantRestricted Stock Units · Derivative | 204,918 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001103021-22-000020 · wf-form4_164367002807246.xml · derivative · entry 2 Bailey Jeffrey Allen · CIK 0001500210 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,918 Underlying: Common Stock · 204,918 shares Expires 2025-01-27 F3 · kind: The Restricted Stock Units ("RSUs") were issued to the Reporting Person on January 27, 2022, pursuant to a grant under the Plan. The award is subject to time-based vesting and will vest in equal portions on: (i) January 27, 2023; (ii) January 27, 2024; and (iii) January 27, 2025. F4 · derivative.exercise_date: Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 18:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantStock Options (right to buy) · Derivative | 1,143,467 | $3.66 Strike: $3.66 | $4,185,089.22 |
DisclosureSEC source: 0001103021-22-000020 · wf-form4_164367002807246.xml · derivative · entry 1 Bailey Jeffrey Allen · CIK 0001500210 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,143,467 Underlying: Common Stock · 1,143,467 shares Expires 2032-01-26 F1 · derivative.exercise_price: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on January 27, 2022. F2 · kind: The stock options were issued to the Reporting Person on January 27, 2022, pursuant to a grant under the Issuer's 2019 Stock Option Incentive Plan (the "Plan"). The award is subject to time-based vesting and will vest in equal portions on: (i) January 27, 2023; (ii) January 27, 2024; and (iii) January 27, 2025. F2 · derivative.exercise_date: The stock options were issued to the Reporting Person on January 27, 2022, pursuant to a grant under the Issuer's 2019 Stock Option Incentive Plan (the "Plan"). The award is subject to time-based vesting and will vest in equal portions on: (i) January 27, 2023; (ii) January 27, 2024; and (iii) January 27, 2025. Read SEC document |
| November 04, 2021 Filed Nov 8, 2021 16:40 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 53,333 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-022261 · wf-form4_163640762663267.xml · derivative · entry 2 Bailey Jeffrey Allen · CIK 0001500210 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,667 Underlying: Common Stock · 53,333 shares Expires 2023-11-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person on November 4, 2020, under the Issuer's 2019 Stock Option Incentive Plan. The remaining RSUs vest equally on November 4, 2022 and November 4, 2023. Read SEC document |
| November 04, 2021 Filed Nov 8, 2021 16:40 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 53,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-022261 · wf-form4_163640762663267.xml · nonDerivative · entry 1 Bailey Jeffrey Allen · CIK 0001500210 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person on November 4, 2020, under the Issuer's 2019 Stock Option Incentive Plan. The remaining RSUs vest equally on November 4, 2022 and November 4, 2023. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 18:23 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 5,567 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001103021-21-000076 · wf-form4_162863417092823.xml · derivative · entry 2 Bailey Jeffrey Allen · CIK 0001500210 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,567 shares Expires 2021-08-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units granted to the Reporting Person on July 30, 2020 under the Issuer's 2019 Stock Option Incentive Plan. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 18:23 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 5,567 | $0.00 | $0.00 |
DisclosureSEC source: 0001103021-21-000076 · wf-form4_162863417092823.xml · nonDerivative · entry 1 Bailey Jeffrey Allen · CIK 0001500210 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 23:58 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 96,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0000899243-21-024533 · doc4.xml · derivative · entry 1 Bailey Jeffrey Allen · CIK 0001500210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,000 Underlying: Common Stock · 96,000 shares Expires 2031-06-14 F1 · derivative.exercise_date: This option was granted on June 15, 2021. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 15, 2022 or (ii) the date of the Issuer's 2022 Annual Meeting of Stockholders. Read SEC document |
| April 06, 2021 Filed Apr 8, 2021 20:29 UTC | abrdn World Healthcare Fund THW · Entity 5390 | OtherSubscription Rights · Derivative | 735 | $0.00 Strike: $14.26 | $0.00 |
DisclosureSEC source: 0001104659-21-048077 · tm2111500-5_4seq1.xml · derivative · entry 2 Bailey Jeffrey Allen · CIK 0001500210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Shares of Benefitial Interest · 245 shares Expires 2021-04-06 Read SEC document |
| April 06, 2021 Filed Apr 8, 2021 20:29 UTC | abrdn World Healthcare Fund THW · Entity 5390 | OtherShares of Beneficial Interest | 245 | $14.26 | $3,494.19 |
DisclosureSEC source: 0001104659-21-048077 · tm2111500-5_4seq1.xml · nonDerivative · entry 1 Bailey Jeffrey Allen · CIK 0001500210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 980 Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 16:14 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 5,333 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001103021-21-000031 · wf-form4_161549726753284.xml · derivative · entry 2 Bailey Jeffrey Allen · CIK 0001500210 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,667 Underlying: Common Stock · 5,333 shares Expires 2023-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 5,333 of RSUs granted to the Reporting Person on March 9, 2020 under the Stock Option Incentive Plan. The remainder of the RSUs under this grant will vest in equal amounts on each of March 9, 2022 and March 9, 2023. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 16:14 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 5,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001103021-21-000031 · wf-form4_161549726753284.xml · nonDerivative · entry 1 Bailey Jeffrey Allen · CIK 0001500210 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 16:41 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 10,000 | $4.35 | $43,500.00 |
DisclosureSEC source: 0001103021-20-000158 · wf-form4_160815487692282.xml · nonDerivative · entry 1 Bailey Jeffrey Allen · CIK 0001500210 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,567 Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 17:21 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantRestricted Stock Units · Derivative | 160,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001103021-20-000150 · wf-form4_160470129788573.xml · derivative · entry 4 Bailey Jeffrey Allen · CIK 0001500210 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2023-11-04 F3 · derivative.exercise_price: The stock options and RSUs were issued to the Reporting Person on November 4, 2020, pursuant to a grant under the Plan and are subject to vesting in thirds on each of November 4, 2021, November 4, 2022 and November 4, 2023. F3 · derivative.exercise_date: The stock options and RSUs were issued to the Reporting Person on November 4, 2020, pursuant to a grant under the Plan and are subject to vesting in thirds on each of November 4, 2021, November 4, 2022 and November 4, 2023. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 17:21 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantStock Options (right to buy) · Derivative | 840,000 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001103021-20-000150 · wf-form4_160470129788573.xml · derivative · entry 3 Bailey Jeffrey Allen · CIK 0001500210 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 840,000 Underlying: Common Stock · 840,000 shares Expires 2030-11-04 F2 · derivative.exercise_price: The exercise price of the stock options issued to the Reporting Person is the volume-weighted average price of the Company's common stock for the 30-day period preceding November 4, 2020. F3 · derivative.exercise_date: The stock options and RSUs were issued to the Reporting Person on November 4, 2020, pursuant to a grant under the Plan and are subject to vesting in thirds on each of November 4, 2021, November 4, 2022 and November 4, 2023. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 17:21 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001103021-20-000150 · wf-form4_160470129788573.xml · derivative · entry 2 Bailey Jeffrey Allen · CIK 0001500210 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2022-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Restricted Stock Units ("RSUs") were issued to the Reporting Person on May 10, 2020, pursuant to a grant under the Issuer's 2019 Stock Option Plan (the "Plan"). Pursuant to the execution of an amended offer letter, the RSUs have fully vested on November 4, 2020. F1 · derivative.exercise_date: The Restricted Stock Units ("RSUs") were issued to the Reporting Person on May 10, 2020, pursuant to a grant under the Issuer's 2019 Stock Option Plan (the "Plan"). Pursuant to the execution of an amended offer letter, the RSUs have fully vested on November 4, 2020. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 17:21 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001103021-20-000150 · wf-form4_160470129788573.xml · nonDerivative · entry 1 Bailey Jeffrey Allen · CIK 0001500210 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,567 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 23, 2020 Filed Sep 23, 2020 19:56 UTC | abrdn Healthcare Investors HQH · Entity 8816 | PurchaseShares of Beneficial Interest | 490 | $20.39 | $9,991.10 |
DisclosureSEC source: 0001104659-20-107790 · a4.xml · nonDerivative · entry 1 Bailey Jeffrey Allen · CIK 0001500210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 490 Read SEC document |
| September 23, 2020 Filed Sep 23, 2020 19:57 UTC | abrdn World Healthcare Fund THW · Entity 5390 | PurchaseShares of Beneficial Interest | 710 | $14.18 | $10,067.80 |
DisclosureSEC source: 0001104659-20-107792 · a4.xml · nonDerivative · entry 1 Bailey Jeffrey Allen · CIK 0001500210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 710 Read SEC document |
| September 23, 2020 Filed Sep 23, 2020 19:57 UTC | abrdn Healthcare Opportunities Fund THQ · Entity 5102 | PurchaseShares of Beneficial Interest | 570 | $17.68 | $10,077.60 |
DisclosureSEC source: 0001104659-20-107791 · a4.xml · nonDerivative · entry 1 Bailey Jeffrey Allen · CIK 0001500210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 570 Read SEC document |
| September 22, 2020 Filed Sep 23, 2020 19:56 UTC | abrdn Life Sciences Investors HQL · Entity 8835 | PurchaseShares of Beneficial Interest | 580 | $17.28 | $10,022.40 |
DisclosureSEC source: 0001104659-20-107789 · a4.xml · nonDerivative · entry 1 Bailey Jeffrey Allen · CIK 0001500210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580 Read SEC document |
| August 07, 2020 Filed Aug 11, 2020 16:53 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 5,567 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001103021-20-000125 · wf-form4_159717917539790.xml · derivative · entry 2 Bailey Jeffrey Allen · CIK 0001500210 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,567 Underlying: Common Stock · 5,567 shares Expires 2021-08-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units ("RSUs") were issued to the Reporting Person on July 30, 2020, as compensation for service on the Issuer's board of directors. The remaining RSUs will vest in the first open window following the Company's 2021 Annual Meeting of Stockholders. Read SEC document |
| August 07, 2020 Filed Aug 11, 2020 16:53 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 5,567 | $0.00 | $0.00 |
DisclosureSEC source: 0001103021-20-000125 · wf-form4_159717917539790.xml · nonDerivative · entry 1 Bailey Jeffrey Allen · CIK 0001500210 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,567 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2020 Filed Aug 3, 2020 17:47 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantRestricted Stock Units · Derivative | 11,134 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001103021-20-000110 · wf-form4_159649124172777.xml · derivative · entry 2 Bailey Jeffrey Allen · CIK 0001500210 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,134 Underlying: Common Stock · 11,134 shares Expires 2021-08-06 F2 · derivative.exercise_date: The restricted stock units ("RSUs") were issued to the Reporting Person on July 30, 2020, pursuant to a grant under the Company's 2019 Stock Option Incentive Plan. The awards are subject to time-based vesting and will vest as follows: (i) 5,567 RSUs vest in the first open window following the filing of the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, and (ii) 5,567 RSUs vest in the first open window following the Company's 2021 Annual Meeting of Stockholders. Read SEC document |
| July 30, 2020 Filed Aug 3, 2020 17:47 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantStock Options (right to buy) · Derivative | 66,805 | $0.00 Strike: $4.36 | $0.00 |
DisclosureSEC source: 0001103021-20-000110 · wf-form4_159649124172777.xml · derivative · entry 1 Bailey Jeffrey Allen · CIK 0001500210 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,805 Underlying: Common Stock · 66,805 shares Expires 2030-07-29 F1 · derivative.exercise_date: The stock options ("options") were issued to the Reporting Person on July 30, 2020, pursuant to a grant under the Company's 2019 Stock Option Incentive Plan. The awards are subject to time-based vesting and will vest as follows: (i) 33,403 options vest in the first open window following the filing of the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, and (ii) 33,402 options vest in the first open window following the Company's 2021 Annual Meeting of Stockholders. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 20:30 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0000899243-20-017080 · doc4.xml · derivative · entry 1 Bailey Jeffrey Allen · CIK 0001500210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2030-06-16 F1 · derivative.exercise_date: This option was granted on June 17, 2020. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 17, 2021 or (ii) the date of the Issuer's 2021 Annual Meeting of Stockholders. Read SEC document |
| May 10, 2020 Filed May 12, 2020 19:37 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantRestricted Stock Units · Derivative | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001103021-20-000083 · wf-form4_158932661908925.xml · derivative · entry 2 Bailey Jeffrey Allen · CIK 0001500210 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2022-05-10 F3 · derivative.exercise_price: The Restricted Stock Units ("RSUs") were issued to the Reporting Person on May 10, 2020, pursuant to a grant under the Plan. The award is subject to time-based vesting and will vest in equal portions on: (i) May 10, 2021; and (ii) May 10, 2022. F3 · price: The Restricted Stock Units ("RSUs") were issued to the Reporting Person on May 10, 2020, pursuant to a grant under the Plan. The award is subject to time-based vesting and will vest in equal portions on: (i) May 10, 2021; and (ii) May 10, 2022. F3 · derivative.exercise_date: The Restricted Stock Units ("RSUs") were issued to the Reporting Person on May 10, 2020, pursuant to a grant under the Plan. The award is subject to time-based vesting and will vest in equal portions on: (i) May 10, 2021; and (ii) May 10, 2022. Read SEC document |
| May 10, 2020 Filed May 12, 2020 19:37 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantStock Options (right to buy) · Derivative | 160,000 | $0.00 Strike: $4.23 | $0.00 |
DisclosureSEC source: 0001103021-20-000083 · wf-form4_158932661908925.xml · derivative · entry 1 Bailey Jeffrey Allen · CIK 0001500210 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2030-05-09 F1 · derivative.exercise_price: The exercise price of the stock options issued to the Reporting Person is the volume-weighted average price of the Company's common stock for the 30-day period preceding May 10, 2020. F2 · derivative.exercise_date: The Performance-based stock options were issued to the Reporting Person on May 10, 2020, pursuant to a grant under the Issuer's 2019 Stock Option Incentive Plan, as amended (the "Plan") and vests as follows: i) Up to 50% of the performance-based options will vest following the Board's year-end review of the Reporting Person's performance as CEO in 2020 and ii) up to 50% of the performance-based options will vest subject to the Board's determination of the Reporting Person's satisfactory performance during such CEO's first six months. Read SEC document |
| March 09, 2020 Filed Mar 17, 2020 16:26 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantRestricted Stock Units · Derivative | 16,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001103021-20-000046 · wf-form4_158447674471808.xml · derivative · entry 2 Bailey Jeffrey Allen · CIK 0001500210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2023-03-08 F1 · derivative.exercise_date: The stock options and restricted stock were issued to the Reporting Person on March 9, 2020, pursuant to a grant under the Issuer's 2019 Stock Option Incentive Plan (the "Plan"). The award is subject to time-based vesting and will vest in equal portions on: (i) March 9, 2021; (ii) March 9, 2022; and (iii) March 9, 2023. Read SEC document |
| March 09, 2020 Filed Mar 17, 2020 16:26 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantStock Options (right to buy) · Derivative | 96,000 | $0.00 Strike: $5.18 | $0.00 |
DisclosureSEC source: 0001103021-20-000046 · wf-form4_158447674471808.xml · derivative · entry 1 Bailey Jeffrey Allen · CIK 0001500210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,000 Underlying: Common Stock · 96,000 shares Expires 2030-03-08 F1 · derivative.exercise_date: The stock options and restricted stock were issued to the Reporting Person on March 9, 2020, pursuant to a grant under the Issuer's 2019 Stock Option Incentive Plan (the "Plan"). The award is subject to time-based vesting and will vest in equal portions on: (i) March 9, 2021; (ii) March 9, 2022; and (iii) March 9, 2023. Read SEC document |
| November 15, 2019 Filed Nov 18, 2019 21:15 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | PurchaseCommon Stock | 39,142 | $0.51 | $19,962.42 |
DisclosureSEC source: 0000899243-19-027510 · doc4.xml · nonDerivative · entry 2 Bailey Jeffrey Allen · CIK 0001500210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,894 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.